| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/01/2014 | EP2678327A1 Heteroaryl derivatives as alpha7 nachr modulators |
| 01/01/2014 | EP2678319A2 Antibiotic tolerance inhibitors |
| 01/01/2014 | EP2678318A1 Cannabinoid receptor modulators |
| 01/01/2014 | EP2678317A1 Benzamide derivatives as p2x7 receptor antagonists |
| 01/01/2014 | EP2678316A2 Substituted aromatic sulfur compounds and methods of their use |
| 01/01/2014 | EP2678315A2 (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR |
| 01/01/2014 | EP2678307A1 Use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment |
| 01/01/2014 | EP2678297A2 Chrysophaentin analogs that inhibit ftsz protein |
| 01/01/2014 | EP2678075A1 Solid forms of a pharmaceutically active substance |
| 01/01/2014 | EP2678021A2 Phosphorus containing compounds as protein kinase inhibitors |
| 01/01/2014 | EP2678020A2 Formulations useful for spray drying vaccines |
| 01/01/2014 | EP2678019A2 Method and cells for identifying rig-i pathway regulators |
| 01/01/2014 | EP2678018A1 Combination of kanase inhibitors and uses thereof |
| 01/01/2014 | EP2678017A2 Asymmetric ureas and medical uses thereof |
| 01/01/2014 | EP2678016A2 Heterocyclic compounds and uses thereof |
| 01/01/2014 | EP2678015A1 Use of nifuratel to treat infections caused by clostridium species |
| 01/01/2014 | EP2678014A2 Prostate cancer therapy with hsp90 inhibitory compounds |
| 01/01/2014 | EP2678013A1 Combination therapy of hsp90 inhibitory compounds with radiotherapy |
| 01/01/2014 | EP2678012A1 C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection |
| 01/01/2014 | EP2678011A1 Antitumoral combination comprising cabazitaxel and cisplatin |
| 01/01/2014 | EP2678010A1 Composition to increase joint and/or postural stability |
| 01/01/2014 | EP2678009A1 Cystamine analogues for the treatment of parkinson's disease |
| 01/01/2014 | EP2678007A2 Protein nanocarriers for topical delivery |
| 01/01/2014 | EP2678006A1 Packaging of solid pharmaceutical preparations containing the active substance glyceryl trinitrate |
| 01/01/2014 | EP2678004A1 Nanocapsulation of essential oils for preventing or curing infectious diseases alone or with an antibiotic |
| 01/01/2014 | EP2678001A2 Polymer conjugated protein micelles |
| 01/01/2014 | EP2678000A1 Stabilized granules containing glyceryl trinitrate |
| 01/01/2014 | EP2677884A1 Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients |
| 01/01/2014 | EP2677868A2 Pharmaceutical compositions of maraviroc and process for the preparation thereof |
| 01/01/2014 | EP2677865A1 Inhibitors of bromodomains as modulators of gene expression |
| 01/01/2014 | EP2133330B1 Atropisomer of pyrrole derivative |
| 01/01/2014 | EP1682573B1 The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases |
| 01/01/2014 | CN103492404A C-4" position substituted macrolide derivative |
| 01/01/2014 | CN103492392A Thieno [2, 3 -d] pyrimidine derivatives and their use to treat arrhythmia |
| 01/01/2014 | CN103492390A Fluorophenyl bicyclic heteroaryl compounds |
| 01/01/2014 | CN103492389A Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
| 01/01/2014 | CN103492388A Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors |
| 01/01/2014 | CN103492386A Novel compound useful for the treatment of degenerative and inflammatory diseases |
| 01/01/2014 | CN103492385A Novel compound useful for the treatment of degenerative and inflammatory diseases |
| 01/01/2014 | CN103492382A Inhibitors of influenza viruses replication |
| 01/01/2014 | CN103492381A Inhibitors of influenza viruses replication |
| 01/01/2014 | CN103492377A Triazolopyridine compounds as PIM kinase inhibitors |
| 01/01/2014 | CN103492375A Pyrazole derivatives, preparation method thereof, and composition for preventing and treating osteoporosis containing same |
| 01/01/2014 | CN103492374A Pyrazolidin-3-one derivatives |
| 01/01/2014 | CN103492373A Ethynyl derivatives as positive allosteric modulators of the MGLUR5 |
| 01/01/2014 | CN103492372A Androgen receptor modulating carboxamides |
| 01/01/2014 | CN103492369A Cannabinoid receptor modulators |
| 01/01/2014 | CN103492368A Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
| 01/01/2014 | CN103492367A Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy |
| 01/01/2014 | CN103492366A Primary amine diazeniumdiolate heterocyclic derivatives |
| 01/01/2014 | CN103492365A Substituted diphenyl derivatives |
| 01/01/2014 | CN103492358A Use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment |
| 01/01/2014 | CN103492028A Novel sulfonaminoquinoline hepcidin antagonists |
| 01/01/2014 | CN103491982A In vivo polynucleotide delivery conjugates having enzyme sensitive linkages |
| 01/01/2014 | CN103491981A Cellular hydration compositions containing cyclodextrins |
| 01/01/2014 | CN103491980A Photodynamic therapy or diagnostic agent, using infrared-spectrum light |
| 01/01/2014 | CN103491972A Granules in liquid dosage form |
| 01/01/2014 | CN103491967A Artificial saliva comprising hyaluronic acid |
| 01/01/2014 | CN103491966A Selection of HCV treatment |
| 01/01/2014 | CN103491965A Method and cells for identifying rig-i pathway regulators |
| 01/01/2014 | CN103491964A Solid dispersion formulations and methods of use thereof |
| 01/01/2014 | CN103491963A Processes for the preparation of enamines |
| 01/01/2014 | CN103491962A Combination of kanase inhibitors and uses threof |
| 01/01/2014 | CN103491961A Aripiprazole compositions and methods for its transdermal delivery |
| 01/01/2014 | CN103491960A Therapeutic compounds and compositions |
| 01/01/2014 | CN103491959A Trpm5 inhibitors support body weight reduction without reducing food intake |
| 01/01/2014 | CN103491958A Pouch containing nicotine in free salt form |
| 01/01/2014 | CN103491957A Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins |
| 01/01/2014 | CN103491956A Inhibitors of viral entry into mammalian cells |
| 01/01/2014 | CN103491955A Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
| 01/01/2014 | CN103491954A Use of L-carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function |
| 01/01/2014 | CN103491953A Pharmaceutical preparation |
| 01/01/2014 | CN103491952A Novel combination therapy for the treatment of cancer |
| 01/01/2014 | CN103491948A Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
| 01/01/2014 | CN103491945A Non-aqueous silicone-based ophthalmic formulations |
| 01/01/2014 | CN103491804A Nutritional compositions having alpha-HICA and eicosapentaenoic acid |
| 01/01/2014 | CN103491801A Beadlets comprising carotenoids |
| 01/01/2014 | CN103491782A Pesticidal compositions and processes related thereto |
| 01/01/2014 | CN103491778A Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use |
| 01/01/2014 | CN103491777A Cathepsin c inhibitors |
| 01/01/2014 | CN103491772A Derivatives of sulindac, use thereof and preparation thereof |
| 01/01/2014 | CN103484308A Health-care wine and preparation method thereof |
| 01/01/2014 | CN103483582A Biodegradable polymer vesicle with pH responsiveness, and preparation method and application thereof |
| 01/01/2014 | CN103483487A Novel structure product, preparation method and use of styrenic resin |
| 01/01/2014 | CN103483462A Preparation method for phascolosoma esculenta polysaccharide and application of phascolosoma esculenta polysaccharide in treating septicemia |
| 01/01/2014 | CN103483460A Preparation method of ulva fasciata delile sulfated polysaccharide with anti-tumor activity |
| 01/01/2014 | CN103483413A Polyoxypregnane compounds and uses thereof |
| 01/01/2014 | CN103483388A Norharman-ruthenium (II) polypyridine complex with antitumour activity |
| 01/01/2014 | CN103483374A Tributyl tin organic acid ester coordination polymers, and preparation method and application thereof |
| 01/01/2014 | CN103483373A Tributyl tin organic acid esters, and preparation method and application thereof |
| 01/01/2014 | CN103483363A Diverse chiral amino boric acid, preparation method and application thereof |
| 01/01/2014 | CN103483354A Chromones compound, preparing method thereof and chromones compound application in preparing antineoplastic and enzyme inhibitor medicines |
| 01/01/2014 | CN103483353A Dithiolopyrrolone compound nanoparticles and preparation method thereof |
| 01/01/2014 | CN103483352A Medicinal bulk drug for resisting tumors |
| 01/01/2014 | CN103483345A Phosphoinositide 3-kinase (P13K) inhibitor, pharmaceutical composition containing P13K inhibitor, and application of phosphoinositide kinase inhibitor and pharmaceutical composition |
| 01/01/2014 | CN103483343A Compounds for inhibiting mitotic progression |
| 01/01/2014 | CN103483335A Columbamine II derivatives and preparation method and application thereof |
| 01/01/2014 | CN103483334A Crystal form of penehyclidine hydrochloride racemic mixture II and preparation method thereof |
| 01/01/2014 | CN103483333A Crystal form of penehyclidine hydrochloride racemic mixture I and preparation method thereof |
| 01/01/2014 | CN103483329A Furanone-aryl-oxazolidinone type compound as well as preparation method and application thereof |